Stock analysts at Barclays started coverage on shares of Express Scripts (NASDAQ:ESRX) in a research note issued to investors on Thursday, MarketBeat reports. The firm set an “equal weight” rating and a $84.00 price target on the stock. Barclays’ price objective suggests a potential upside of 4.02% from the company’s current price.
A number of other equities research analysts also recently commented on the company. Zacks Investment Research raised Express Scripts from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a report on Tuesday. Maxim Group lifted their target price on Express Scripts from $87.00 to $101.00 in a report on Wednesday, February 28th. Jefferies Group set a $91.00 target price on Express Scripts and gave the stock a “buy” rating in a report on Wednesday, February 28th. Bank of America started coverage on Express Scripts in a research report on Tuesday, February 27th. They set an “underperform” rating and a $77.00 price target for the company. Finally, BidaskClub upgraded Express Scripts from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $81.97.
Shares of Express Scripts (NASDAQ ESRX) opened at $80.75 on Thursday. The company has a current ratio of 0.67, a quick ratio of 0.55 and a debt-to-equity ratio of 0.83. Express Scripts has a twelve month low of $55.80 and a twelve month high of $85.07. The company has a market capitalization of $44,989.74, a PE ratio of 11.20, a P/E/G ratio of 0.98 and a beta of 0.94.
Express Scripts announced that its board has approved a share buyback plan on Monday, December 18th that allows the company to repurchase 45,000,000 shares. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.
In other news, VP Christine Houston sold 10,104 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $70.08, for a total value of $708,088.32. Following the completion of the sale, the vice president now directly owns 87,400 shares in the company, valued at $6,124,992. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Everett Neville sold 4,895 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $75.26, for a total value of $368,397.70. The disclosure for this sale can be found here. Insiders sold 21,896 shares of company stock valued at $1,617,903 over the last 90 days. Company insiders own 0.68% of the company’s stock.
Several institutional investors have recently bought and sold shares of ESRX. SeaCrest Wealth Management LLC purchased a new stake in shares of Express Scripts in the fourth quarter valued at approximately $105,000. Bank of Nova Scotia Trust Co. purchased a new stake in shares of Express Scripts in the third quarter valued at approximately $120,000. Aevitas Wealth Management Inc. purchased a new stake in shares of Express Scripts in the fourth quarter valued at approximately $128,000. Financial Gravity Companies Inc. purchased a new stake in shares of Express Scripts in the fourth quarter valued at approximately $142,000. Finally, Monroe Bank & Trust MI increased its position in shares of Express Scripts by 74.8% in the third quarter. Monroe Bank & Trust MI now owns 2,266 shares of the company’s stock valued at $156,000 after buying an additional 970 shares in the last quarter. Institutional investors and hedge funds own 87.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/03/10/express-scripts-esrx-receives-new-coverage-from-analysts-at-barclays.html.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.